Full commercial access secured in Germany; Market access granted in France through a reimbursed Early Access Program

Read press release

Hansa Biopharma published its Q1 report on April 21, 2022. Access to the report and conference call here.

Read report and view webcast

Updated company collected consensus available from 8 banks and research institutions

Read more

Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease

Read press release

Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa’s desensitization treatment for kidney transplant in Central Eastern Europe and Israel

Read press release

Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-GBM after FDA acceptance of IND application

Read press release

Watch interview with CEO Søren Tulstrup following the Q1 report

Interview

Hansa Biopharma at a Glance

Hansa Biopharma is leveraging its proprietary enzyme technology platform to enable immunomodulatory treatments for transplants, rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer.

The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. The European Commission has conditionally approved Idefirix (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.

Hansa’s research and development program is also advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.



Our Equity Story

Imlifidase works
Targeting rare diseases with a high unmet medical need
Addresses a clear unmet need
Commercialize Idefirix® in first markets and indications
Well positioned for commercial success
Evolution into a fully integrated biopharmaceutical company
Rich pipeline
Leveraging our proprietary antibody cleaving enzyme technology

Learn More

Latest Financial Results

View All Results
View all news

Latest News

View all events

Upcoming Events

Milestones and near-term news flow

For any investor related inquiries, please contact IR@hansabiopharma.com